



PRESS RELEASE

27 August 2024 11:10:00 CEST

The leading diagnostics company Werfen launches groundbreaking POC system with integrated acoustofluidic technology

Over the past years, AcouSort and Werfen have collaborated on the use of acoustofluidics technology to enable hemolysis detection in point-of-care (POC) diagnostic instruments. Using AcouSort background technology, the parties have jointly developed the acoustofluidic technology now implemented in Werfen’s groundbreaking GEM Premier 7000 system for point-of-care blood gas analysis. The new system was introduced at the 2024 Association for Laboratory Medicine (ADLM) Annual Meeting (formerly the American Association for Clinical Chemistry).

The lack of hemolysis detection in point-of-care blood gas testing has been widely recognized as a significant problem. The potential value of hemolysis detection is tremendous but has been viewed as an unsolvable challenge – until now.

The hemolysis detection in GEM Premier 7000 is based upon patented acoustofluidic technology for plasma separation, combined with photometric determination. In just 45 seconds, the GEM Premier 7000 detects hemolysis, while delivering a complete menu of results (pH, pO₂, pO₂, sodium, potassium, ionized calcium, chloride, glucose, lactate, hematocrit, total hemoglobin, total bilirubin and CO-Oximetry).

AcouSort will receive per product royalties from each sale of products containing the acoustofluidics technology. And since the acoustofluidics technology in the system is semi-disposable, AcouSort expects to see growth in revenue as the installed base of the system expands. For AcouSort, minimum royalties from the collaboration will be SEK 3.55 million already in the launch year 2024.

“At AcouSort, we are extremely proud of the outcome from our collaboration with Werfen and our contribution to the acoustofluidic elements of the product. With the introduction of GEM Premier 7000 containing a revolutionary acoustofluidic technology jointly developed by Werfen and AcouSort, we now embark on the commercial phase of this collaboration with a leading life science company,” says AcouSort’s CEO Torsten Freltoft.

Link to Werfen’s [Press Release](#).

FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT:

Torsten Freltoft, CEO

Telephone: +45 2045 0854

E-mail: torsten.freltoft@acousort.com



PRESS RELEASE

27 August 2024 11:10:00 CEST

ABOUT ACOUSORT

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Carnegie Investment Bank AB (publ).